No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Sir, We have shown recently that tau protein hyperphosphorylated at threonine 231 (P-tau231P) in cerebrospinal fluid (CSF), a major candidate marker of Alzheimer's disease (AD), correlates with neurofibrillary pathology in the brain of mostly severely demented AD patients (Buerger et al., 2006). In a clinical study, however, it had been reported earlier, that P-tau subtypes perform differently in the discrimination between mild to moderate AD and comparison groups (Hampel et al., 2004). Recently, Engelborghs and colleagues investigated correlations between CSF levels of P-tau phosphorylated at threonine 181 (P-tau181P), another widely used P-tau candidate marker, and Braak NFT and NP stages (Braak and Braak, 1991) and found no associations (Engelborghs et al., 2007). Therefore, we tested whether CSF P-tau181P correlates with neurofibrillary pathology in our previously studied population. Post-mortem assessed parameters were amount of neurofibrillary tangles (NFT), neuritic plaques (NP), neuropil threads (HP-tau load) and P-tau181P concentration in tissue homogenates measured within the brain of 26 AD patients. The study population, materials and methods as well as statistical analyses were identical to our recent report (Buerger et al., 2006). Levels of P-tau181P in CSF and brain homogenates were determined using a commercially available ELISA (Innotest-Phospho-Tau(181P), Innogenetics, Belgium). To compare tau deposits stained by antibodies against phosphorylated tau at threonine 231 and threonine 181 in the brain of AD patients, additional immunohistochemical staining on tissue samples obtained from temporal cortex of all patients included in the study was carried out. Three different tau antibodies were used: monoclonal PHF-TAU clone AT8 (Innogenetics BR-03) that recognizes PHF-tau and the epitope has been shown to contain serine 202; PHF-TAU clone AT180 (Innogenetics BR-07) that recognizes PHF-tau and the epitope has been determined as being threonine 231; and PHF-TAU clone AT270 (Innogenetics BR-08) that recognizes PHF-tau and the epitope has been determined as being threonine 181. All antibodies were used in dilution of 1/500 and the staining was carried out without pretreatments with incubation overnight. Immunoreactivity was estimated semiquantitatively as mild, moderate or severe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Self-citationHampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · cited 2×
“From a clinical study we know that P-tau subtypes perform differently in the discrimination between AD and comparison groups (Hampel et al., 2004).”
BackgroundResultSelf-citation
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725
Metadata
- Authors
- Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., & Hampel, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- e82-e82
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2108681415
- Cited by
- 56
- References
- 3
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. https://app.cochat.ai/papers/10.1093/brain/awm140
- The paper
- Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., & Hampel, H. (2007). No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. https://doi.org/10.1093/brain/awm140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.